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Abstract
Sex segregation in competitive sports is regarded as fair.  Before puberty boys and girls do not differ in height,
muscle and bone mass.  Testosterone (T) exposure during puberty leads to an ultimate average greater height in men
of 12–15 cm, longer and larger bones and muscle mass and strength and higher hemoglobin levels.  Postpubertal
androgen ablation reverses, at least in part, previous anabolic effects of T on muscle, bone mineral density and
hemoglobin but the long bones remain longer and wider.  T administration dose dependently increases muscle mass
and maximal voluntary strength.  Therefore, exogenous androgens, being performance enhancing drugs, are banned
for all athletes. An issue is the participation in competitive sports of people with errors of sexual differentiation and
particularly transsexuals who have been sex-reassigned.  In view of the effects of T, a clear demarcation is whether
sex reassignment has taken place before or after hormonal puberty.  Pubertal effects of T are in part reversible but
there is no reliable evidence as to its completeness.  The International Olympic Committee (IOC) has taken an
inevitably arbitrary decision with regard to participation of sex-reassigned transsexuals in elite sports: sex reassign-
ment must have taken place at least two years earlier, hormone treatment must be appropriate for the reassigned sex
and the reassigned sex must be legally recognized.  The IOC policy is not binding for other organizations.   (Asian J
Androl 2008 May; 10: 427–432)
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1    Introduction
There is wide agreement that sex segregation in com-
petitive sports is defensible and fair.  As adult men have
inherent performance advantages over women due to
their average greater height and muscle mass and power,
sex specific competitions provide women with a
countervailing advantage.
This difference is largely based on correspondingly
different exposures to androgens from the onset of
puberty. Before puberty boys and girls do not differ in
height, muscle and bone mass [1] though girls have
more truncal fat.  Testosterone (T) exposure during
puberty leads to an ultimate average greater height in
men of 12–15 cm, larger and longer bones and muscle
mass and strength and higher hemoglobin levels.  Clini-
cal and experimental studies show that androgen depri-
vation reverses, at least in part, previous anabolic effects
of T on muscle, bone and hemoglobin [2].  But the pu-
bertal effects of T producing a greater length, diameter
and thickness of bones in men, is not reversed upon an-
drogen ablation.  T administration dose dependently in-
creases muscle mass and maximal voluntary strength but
not fatigability or specific tension [3].
 So, to overcome the physical disadvantages, sex
specific competitions for women are allowed and there
is therefore a legitimate need to establish the sex of
people who engage in competitive sports.  The ques-
tion is: can this be done in a way that is scientifically
well founded and is fair to those who wish to engage in
competition.
In the vast majority of sports people’s determination
of sex is not an issue.  They will have a history of having
been born and grown up unambiguously as male or
female. The problems arise in those for whom this has
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not been the case.
Genotyping (determination of Barr bodies in buccal
smears) has been the established means of determining
sex for competition in sports.  The results were unsat-
isfactory and as a result this criterion has been dropped
since the year 2000 [4].  Chromosomal sex, when taken
as the sole criterion for the purpose of ensuring fair
competition in sports, is, indeed, not a particularly ad-
equate indicator.  In humans, there is no solid evidence
that the pattern of sex chromosome has a direct effect
on muscle mass and strength.  Rather, the influence is
indirect through determination of the nature of the em-
bryonic gonadal anlagen (testis or ovary) and their hor-
monal products (T and estradiol and their quantitative
relationship).  Also other criteria (the nature of the gonad,
sex hormones and genitalia) do not provide workable
criteria to determine sex and gender of human beings.
The implication is that in humans, manhood and wom-
anhood cannot be assessed by laboratory techniques
alone but require additionally a self-description of one’s
gender identity/role.  In sports, previous and present
exposure to androgens is a reasonable criterion for re-
ducing unfair competition.  In a series of studies Bhasin
and coworkers [5] have demonstrated that there is a
positive correlation between blood T concentrations and
leg press strength, thigh and quadriceps muscle volume,
and levels of hemoglobin and insulin-like growth fac-
tor-1 (IGF-1),  and that the anabolic response to T can
largely be predicted by the dose administered [6].  This
dose-response curve between T and muscle properties
goes linearly beyond the physiological range but does
not seem to apply to bones mass/strength.
2    People with disorders of sexual differentiation
and sports
Some children are born with ambiguous genitalia, a
perplexing discovery for parents.  A child born with am-
biguous genitalia constitutes a psychosocial emergency
in which sex assignment must take place without much
delay, rather over days than over weeks.  A socio-cul-
tural given of the human condition is an absolute di-
chotomy between male and female with regard to sex.
In cases of genital ambiguity, modern techniques such
as karyotyping, molecular biology, and imaging tech-
niques allow a rather precise diagnosis of the condition,
but decisions regarding sex assignment are still based on
very limited empiric data [7].
 The widely adopted policy nowadays is to arrive at
a prognosis on the “optimal sex” for the newborn, the
elements of which are an overall sex-appropriate appear-
ance with stable gender identity, good sexual function
(preferably combined with reproductive function if
attainable), minimal medical procedures, and a reasona-
bly happy life given the limitations [7].   To those with-
out experience in this area this policy might seem erratic,
but the outcome studies show that this is an acceptable
practice for patients, though there should be room for
later sex reassignment if the subject experiences the as-
signed sex as incongruous [8, 9].  The implication of
contemporary medical practice is that, ultimately, there
is no single solid biological criterion for the determina-
tion of sex for the purpose of sex assignment of children
with genital ambiguity.  When a criterion is needed for
sex for a specific purpose, the optimal solution seems to
be to adopt a criterion that serves best the purpose for
which it is needed.  In sports, previous and present ex-
posure to androgens is a reasonable criterion for reduc-
ing unfair competition.  Nowadays most intersexed sub-
jects are identified early in life, if not immediately
postnatally.  Usually, before they engage in sports, they
have received long-term endocrine treatment, the nature
of which being determined by their sex of assignment.
This is consistent with the International Olympic
Committee’s (IOC) policy on gender verification requir-
ing a two-year period of stable gender re-assigment.
3    Transsexualism
Transsexualism is the condition in which a person
with apparently normal somatic sexual differentiation has
the unshakeable conviction that he or she is actually a
member of the other sex.  This conviction is accompa-
nied by the irresistible urge to live in the gender experien-
ced as self, which requires hormonal, anatomical, legal,
and psychosocial adaptations.  Psychological assessment
may conclude that sex reassignment will bring relief to
an individual suffering from gender dysphoria–the ex-
treme feeling often described as being “trapped in the
wrong body”–and may result in an indication for hor-
mone and surgical treatment of transsexuals.
Increasingly, countries are offering transsexuals who
have undergone sex reassignment procedures, the pos-
sibility to change their legal sex to allow them to take
part in public life, with the same rights as anyone born
into that sex.  The practical implementation of this policy
may involve complex and difficult decisions.  As with
other intersexed individuals, the medical and legal sys-
tem is being called upon to humanely provide a safe space
for these people to function as men or women with as
little needless hindrance as possible, yet consistent with
the gender bipolarity of modern human society.
 The acquisition of the secondary sex characteris-
tics of the other gender, to the fullest extent possible, is
fundamental to sex reassignment for the transsexual
patient.  Obviously, acquisition of these secondary sex
characteristics is contingent on sex steroids.  At least in
the rat, no essential difference in sensitivity to the bio-
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logical action of sex steroids on the basis of genetic con-
figurations or gonadal status has been demonstrated [10].
The typical transsexual requesting treatment is a young
to middle-aged and usually healthy person.
4    Physical changes following administration of
cross-sex hormones postpubertally
Since 1975, the gender clinic of the Vrije Universiteit
in Amsterdam, the Netherlands, has provided sex reas-
signment treatment to more than 3 000 transgendered
people.
The physical changes resulting from cross-sex hor-
mone administration have been reported [11–13].  The
standard hormone treatment before sex reassignment
surgery in male-to-female transsexuals (M2F) is combi-
nation of anti-androgen with estrogens.  In Europe, the
most widely-used drug is cyproterone acetate (usually
50 mg twice daily), a progestational compound with anti-
androgenic properties.  If not available, medroxy-
progesterone acetate, 5 to 10 mg/day, is a less effective
alternative.  Long-acting gonadotrophin-releasing hor-
mone agonists (GnRH), injected monthly, also inhibit go-
nadotropin secretion [14].  Finasteride (5 mg/day), a 5α-
reductase inhibitor, might also be considered. The latter
drug but none of those mentioned previously are banned
by the IOC.  Sex reassignment surgery including
gonadectomy, usually takes place following two years
of cross-sex hormones.  Then anti-androgen treatment
in M2F transsexuals is usually stopped, while estrogen
treatment continues.
Female-to-male transsexuals (F2M) receive treatment
with T.  The most commonly used preparations are T
esters, an injectable administered intramuscularly in doses
of 200 to 250 mg every two weeks. In some countries,
parenteral T undecanoate (1 000 mg) is available, and
injections may be spaced at 10–12 weeks [15, 16].  Af-
ter ovariectomy, androgen treatment in F2M subjects is
continued at a dosage level as administered to hypogonadal
men.  In this regard the situation of F2M (and intersexed
individuals assigned to the male sex) is comparable to
the situation of agonadal/hypogonadal men receiving T
replacement and would require approval for all elite com-
petitive athletes.
While principally administration of exogenous T is
prohibited for participants in competitive sports, it is the
policy now to allow medically indicated T replacement
in men provided T blood levels have not exceeded and
do not exceed those that naturally occur in men with
normal testicular hormone production.  This goal is dif-
ficult to attain with the traditional T esters whose phar-
macokinetic profile is characterized by peaks and troughs
of circulating levels of T [17].  Use of implantable or
transdermal depot preparations may be more compliant
with this idealized requirement.
5     Physical changes in transsexuals following cross-
sex hormone treatment postpubertally
Androgen deprivation in M2F and androgen admi-
nistration to F2M have consistent effects on the following
variables: plasma T levels, muscle mass measured with
MRI at the level of the thigh, levels of haemoglobin and
IGF-1 [18–20] (Table 1).  The results of androgen depri-
vation plus estrogen treatment in M2F are compared to
the findings in F2M before T administration, and vice versa
the results of T administration in F2M are compared to
the findings in M2F before androgen deprivation plus es-
trogen administration (Table 2).
Androgen deprivation plus estrogen administration of
M2F decreased plasma T to castrate levels and reduced
muscle area significantly after one year of treatment, with
no further reduction after three years of hormones.
Hemoglobin levels decreased significantly and values
after one and three years hormone administration were
not different, and the latter were not different from values
in F2M before T administration.  After one year of cross-
sex hormones values of plasma IGF-1 fell significantly
to levels lower than in F2M before T administration.
In F2M T administration increased plasma T levels
to values above the reference range for eugonadal men
(12–28 nmol/L).  After 1-year muscle area, levels of he-
moglobin and IGF-1 were in the same range as in M2F
before cross-sex hormones, with no further increases in
Table 1. Changes in plasma testosterone (T) and associated changes in biological variables.  All values are means ± SD.  *P < 0.05, baseline
vs. 1 year (Mann-Whitney test), no significant difference between 1 and 3 years.  IGF-1, insulin-like growth factor-1.  Reproduced with
permission from Gooren et al. [20].  © 2004 by Society of the European Journal of Endocrinology.
    Male-to-female transsexuals (n = 19)      Female-to-male transsexuals (n = 17)
    Baseline      1 year      3 years     Baseline      1 year    3 years
Plasma T (nmol/L) 21.5 ± 5.8 1.0 ± 0.0* 0.9 ± 0.1 1.6 ± 0.6 30.8 ± 11.4 30.0 ± 13.0
Muscle area (cm2) 306.9 ± 46.5 277.8 ± 37.0* 271.0 ± 39.0 238.8 ± 33.1 285.3 ± 35.6* 280 ± 39*
Hemoglobin (mmol/L) 9.3 ± 0.7 8.0 ± 0.7* 8.1 ± 0.6 8.2 ± 0.7 9.4 ± 0.8* 9.3 ± 0.9
IGF-1 38.0 ± 10.0 14.0 ± 8.0* 26.0 ± 12.0 36.0 ± 14.0*
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muscle area and hemoglobin levels after 3 years of T
administration.
In spite of the of the cross-sex hormone induced
reduction, mean muscle area in M2F after 1 year of hor-
mones remained significantly greater than in F2M before
T treatment.  Before cross-sex hormone administration
to M2F and F2M there was a large overlap in muscle
area between the two but means were significantly dif-
ferent (Figure 1).  This overlap was almost complete
when androgen deprived M2F were compared to non-
treated F2M, although means remained significantly dif-
ferent (Figure 1).
Our data allow the following conclusions: androgen
deprivation in M2F reduces levels of hemoglobin and
IGF-1 to female levels.  The reduction in muscle area is
significant but mean muscle area remains significantly
higher than in females but showing an almost complete
overlap.  M2F were on average 12 cm taller than F2M.
When androgen deprived M2F were compared to pre-
treatment F2M in a linear regression model, height was a
strong predictor of muscle area (α = 2.29; P = 0.001).
After correction for the effect of gender, the relation
between height and muscle area remained significant
(α = 1.63; P = 0.036).  The reduction in variables three
years after start of cross-sex hormones was not greater
than after one year.
T administration in F2M inducing plasma levels of T
above the references range for eugonadal men increased
muscle area, levels of hemoglobin and IGF-1 to levels of
men.  The increases after three years of T administration
Figure 1. Relative changes in muscle mass after 12-month cross-sex hormonal treatment in 19 male-to-female and 17 female-to-male
transsexual subjects.  The means of 46,XY before testosterone (T) deprivation and 46,XX before T treatment differ with statistical
significance. Beams represent range of all subjects. *P < 0.05, Mann-Whitney test asymp. sig. (two-tailed).  ns: not statistically significant.
Mean in cm2 with SD (whiskers).  Reproduced with permission from Gooren et al. [20].  © 2004 by Society of the European Journal of
Endocrinology.
Table 2. Effects of testosterone (T) administration/deprivation on anthropometric variables.  All values are mean ± SD and 95% confidence
interval (CI) of the difference of the mean.  *P < 0.5, vs. baseline (Mann-Whitney test).  Reproduced with permission from Gooren et al.
[20].  © 2004 by Society of the European Journal of Endocrinology.
         46,XY before T deprivation               46,XY after T deprivation
         vs. 46,XX after T treatment            vs. 46,XX before T treatment
     46,XY      46,XX   95% CI of      46,XY      46,XX  95% CI of
    (n = 19)     (n = 17) the difference     (n = 19)     (n = 17)        the difference
Height (cm) 177.8 ± 7.9 167.1 ± 7.8   5.4–16.0* 177.8 ± 7.9 167.1 ± 7.8 5.8–16.0*
Body weight (kg) 66.1 ± 11.7 63.4 ± 11.4   25.1–10.4 69.9 ± 11.3 60.7 ± 11.8   1.4–16.8*
Body mass index (kg/m2) 20.8 ± 2.6 22.6 ± 3.0   23.7–0.1 22.0 ± 2.7 21.7 ± 3.5 21.7–2.4
Muscle area (cm2 ) 306.9 ± 46.5 285.3 ± 35.6   26.4–49.5 277.8 ± 37.0 238.8 ± 33.1 15.1–62.9*
Serum T (nmol/L) 21.5 ± 5.8 30.8 ± 11.4 215.7–3.0*   1.0 ± 0.0   1.6 ± 0.6 20.9–0.3*
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were not greater than after one year.
We observed an overlap in muscle area between non-
treated M2F and F2M (Figure 1).  Upon androgen depri-
vation of M2F the overlap in muscle area with untreated
F2M was almost complete (Figure 1) though the mean
of the muscle area in androgen-deprived M2F remained
above the mean in untreated F2M, but height was a strong
predictor of muscle mass in both groups.
In the case of transsexuals, the further question
arises whether an individual who has undergone nor-
mal physical pubertal and post-pubertal development in
one sex, with prolonged exposure to sex appropriate
levels of sex steroids before surgical sex reassignment,
can fairly compete as a member of the other sex.  In
terms of actual androgen hormone levels, M2F trans-
sexuals after surgical sex reassignment, have no com-
petitive advantage over other women, but the effects
of prior androgen exposure on muscle mass and strength
do carry over for a certain time period, making this a
relevant consideration.  The fairness of this is subjec-
tive and controversial.
6    Prepubertal administration of cross-sex hormones
The above refers to transsexuals who have under-
gone sex reassignment postpubertally.  Adult transsexu-
als often recall that their gender dysphoria started early
in life, well before puberty.  Children with gender iden-
tity problems increasingly come to the attention of the
psychomedical care system.  From follow-up studies in
cohorts of juvenile transsexuals who have undergone sex-
reassignment treatment, it appears that that they benefit
from somatic treatment [21].  If, in an expert’s opinion,
a child’s cross-sex gender identity will not change dur-
ing long-term follow-up the individual may be spared the
torment of (full) pubescent development of the “wrong”
secondary sex characteristics.  Depot forms of LHRH
antagonists/agonists, following the regimen in children
with precocious puberty, can be used when clear signs
of sexual maturation are evident in order to delay puber-
tal development until an age that a balanced and respon-
sible decision can be made to transition to the other sex
[21].  These juvenile transsexuals have never been ex-
posed to the sex hormones of their natal genetic sex and
their participation in competitive sports is therefore as
much an issue as non-transsexuals who need sex hor-
mone replacement.  Such policies are potentially contro-
versial and are not yet widely adopted.
There will always be an element of arbitrariness in
the drawing of competitive lines.  Different individuals
are born with and develop postnatallly different potentials.
The caprices of genetics and postnatal development will
make any form of competition intrinsically unfair at some
level.  In the studies of Bhasin and coworkers changes in
muscle size correlated with T dose and concentration
[5, 6].  These correlations were established in groups of
men receiving graded doses of T.  There was, however,
considerable heterogeneity in response to T administra-
tion within each group receiving the same amount of T.
These individual differences in response to androgen ad-
ministration might reflect differences in activity level, T
metabolism, nutrition, or polymorphisms in androgen
receptor, myostatin, 5α-reductase, or other muscle growth
regulators.  The length of CAG tract was, however, only
a weak predictor of change in thigh muscle volume and
lean body mass [6].
7    IOC
The IOC approved the expert panel’s recommenda-
tion that postpubertal transsexual individuals, both M2F
and F2M, be eligible to compete under the following cri-
teria [22, 23]:
• Surgical anatomical changes completed, including
external genitalia changes and gonadectomy;
• Legal recognition of their assigned sex has been
conferred by appropriate official authorities;
• Hormonal therapy appropriate for assigned sex has
been administered in a verifiable manner and for a suffi-
cient length of time to reduce to a minimum gender-re-
lated advantages in sport competitions.
Based on the scientific data available, the expert panel
recommended that eligibility should begin no sooner than
2 years after gonadectomy.  Although these criteria have
been widely disseminated in the lay and sports press, not
often appreciated is the fact that the recommendations
included the caveat that every individual would be as-
sessed on a case-by-case basis, in confidence and that,
in the event that the gender of a competing athlete was
questioned, the medical delegate or equivalent of the rele-
vant sporting body would have authority to take all ap-
propriate measures to ascertain the gender of that
competitor.  The following are criteria put in place after
genetic-based laboratory screening of female athletes was
discontinued by the IOC in the year 2000 [4].  The IOC
rules, referred to as the Stockholm consensus are spelled
out on the website: http://www.olympic.org/uk/organisation/
commissions/medical/full_story_uk.asp?id=841.  Other
websites providing information are: http://www.uksport.gov.
uk/assets/File/Generic_Tem-plate_Documents/Stan-
dards_in_Sport/transsexuals.pdf. and http://www.ausport.
gov.au/women/fstrans.asp.
The recommendations are applicable only to elite
competition in events sanctioned by the IOC and, while
not formally binding on other international sports go-
verning bodies, most tend to follow IOC guidelines for
elite sport at international and national level. The further
local application to the entire panoply of sporting events
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may be more flexible.
8    Summary and conclusions
Until 2000 the genetic criterion of sex applied in
competitive sports and precluded the participation of
sex reassigned transsexuals as well as other intersexed
individuals.  While this criterion has been dropped, it
is still regarded as fair, given the physical characteris-
tics of the two sexes, that members of the same sex
compete with each other, except for  types of com-
petitive sports where the physical differences between
men and women offer no advantage or disadvantage.
Presently, greater weight is given to the essence of
the differences in physical properties between men and
women, which is previous and present exposure to the
anabolic effects of androgens.  Upon cessation of the
exposure to androgens, these effects are largely reversi-
ble but is not completely understood whether this
reversibility is truly complete in M2F transsexuals.  F2M
transsexuals, similar  to hypogonadal men, use T
preparation. While their physical properties in the reas-
signed state do not offer an obvious advantage over
men, there is a potential of overdosing T.  The criterion
adopted by the IOC, that in cases of transsexuals a time
span of two years must have been passed, may be an
acceptable compromise where definitive policy could
become intractably difficult.
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